SHOCKING: Is zoetis stock underperforming the s p 500 | Mind Blowing Facts

Valued at a market cap of $75.8 billion, Zoetis Inc. (ZTS) discovers, develops, manufactures, and commercializes animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products. The Parsippany, New Jersey-based company serves both livestock, including cattle, swine, poultry, fish, and sheep, as well as companion animals, such as dogs, cats, and horses.

Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and Zoetis fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - specialty & generic industry. The company stands out as one of the world’s largest animal health companies, with unmatched scale, brand recognition, and product diversity. Its strengths lie in its deep R&D capabilities, allowing it to consistently innovate across therapeutics, vaccines, diagnostics, and genetic testing for both livestock and companion animals. The company benefits from a broad global presence, a diversified portfolio across species and geographies, and strong relationships with veterinarians, farmers, and pet owners.